Phase II Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma

Trial Profile

Phase II Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 May 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Panitumumab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Mar 2018 Planned End Date changed from 1 Aug 2024 to 14 Dec 2023.
    • 27 Mar 2018 Planned primary completion date changed from 1 Aug 2023 to 14 Dec 2020.
    • 19 Mar 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top